UN UNH UnitedHealth Group Loading... : Bullish and Bearish Analyst Opinions

Morgan Stanley raises UnitedHealth target price to 529 dollars from 468 dollars.

Managed care leader, buy on dip.

Buy Medicare Advantage insurers on cost decline.

Chip selloff and AI spending concerns drove a broad market decline, with the Nasdaq 100 falling 1.6% and Alphabet dropping 4.4% on reports its AI model is behind schedule, while TSMC's strong results failed to lift sentiment.

Buy UNH on near-term momentum continuation; Cramer expects further upside support following a strong up day, though no specific fundamental catalyst is cited.

AlphaSense reports that AI in healthcare is delivering measurable ROI across pharma, payers, and providers with real-world implementations at UnitedHealth, Eli Lilly, and Sanofi.

Author sarcastically says "all in" on PYPL and UNH as a joke in reply to a parody post about abandoning AI for consumer staples, not a real position.

US pre-market movers show mixed sector action with TSM down on capex hike despite strong results, UAL lower on light guidance, JBHT up on earnings beat, ATAI surging on LLY acquisition, UNH and ABT rising on strong earnings and outlook, DSGR jumping on buyout, and LULU falling on a Truist downgrade.

Premarket movers report shows mixed Mag 7 stocks, ATAI surging on Eli Lilly acquisition talks, GE and UAL declining on earnings, and UNH rising on raised outlook with peer insurers following.

The author provides a comprehensive macro and market brief highlighting geopolitical escalation, consumer deterioration, and technical fragility from gamma expiry and buyback blackout without stating any personal positions or forward calls.

UnitedHealth stock surges over 8% after reporting stronger than expected second quarter earnings and is now up over 75% since its March bottom.

Retrospective recap of a past buy call on UNH near $290; no current position or forward thesis.

UnitedHealth Group reports second quarter 2026 revenues of 112 billion dollars and raises full year adjusted earnings guidance to a range of 19.50 to 20.00 dollars per share.

UnitedHealth reported second-quarter adjusted earnings per share of 6.38 dollars beating estimates of 4.89 dollars on revenue of 112.03 billion dollars.

UnitedHealth Group reported Q2 2026 adjusted EPS of $6.04 beating estimates of $3.74 and raised its full-year adjusted EPS guidance to $19.50-$20.00 from above $18.25.

UnitedHealth Group reports strong Q2 2026 earnings with adjusted EPS of 6.04 dollars beating estimates of 3.74 dollars and raises full-year guidance.

A single upvoted comment states that UNH “seems” to be recovering. A perceived recovery, if confirmed by price action or fundamentals, could present a short-term buying opportunity as the stock builds from a prior dip. The trade is based on one opinion with minimal supporting data; it signals a cautious opportunity to watch for upward momentum. No counter-arguments exist in the thread, but the lack of corroboration means the recovery could be false or short-lived; broader market factors are unaddressed.

UnitedHealth insurance recovery turnaround.

AlphaSense promotes its real-time earnings call coverage platform ahead of earnings season, listing major companies reporting next week.

A highly upvoted comment says “none of you cucks are talking about UNH” and claims to have bought the bottom last year, now “swimming in cash”. The stock is flying under the radar on WSB despite strong performance, creating a potential follow‑on opportunity. UNH represents a strong bullish pick from a vocal, rewarded community member. No counter‑arguments in the thread; single‑source anecdote. TICKER - MU - SHORT | confidence: 0.60 | sentiment: -0.50 Speaker: r/wallstreetbets community (comments by u/sonsofshiva, u/ercanbas, u/BarbellPadawan – total +16 upvotes) Thesis: Multiple comments: “What in the motherfucking dump is this MU?”, “I’ll buy when it dips… not touching this shit”, and someone sold 1125 strike 1DTE calls (betting against the stock). The community is shocked by the sharp dump, expresses fear of further downside, and actively sells calls – all bearish signals. MU is under heavy selling pressure and skepticism, making a short trade plausible. No bullish counter; potential oversold bounce. The SK hynix IPO commentary may influence the memory sector. TICKER - RIVN - LONG | confidence: 0.50 | sentiment: +0.50 Speaker: r/wallstreetbets community (comment by u/jamaicagroot, +5 upvotes) Thesis: A +5 upvoted comment says “It’s time for all you regards to get in on RIVN”. One vocal champion suggests momentum may be building, though community consensus is thin. A speculative long call based on a single but upvoted voice. Only one comment; no other support or discussion.

A UnitedHealth-commissioned review of its controversial home visits found a lower error rate than government audits, bolstering the company’s defense of the service.

Morgan Stanley raises UnitedHealth PT to $468; speaker includes healthcare in the "own" bucket thematically but provides no specific catalyst for UNH.

Health insurers and drug distributors are undervalued.

The tweet reports a list of stocks receiving analyst upgrades but does not state the author's own position, making it a factual research summary rather than a trade idea.

Luigi Mangione's US criminal trial is set to begin on January 25 2027 shortly after the state case over the death of UnitedHealth Group executive Brian Thompson is expected to conclude.

Buy UNH for diversification from tech-heavy portfolios, benefiting from record-low entry and reduced variance for enhanced geometric returns.

UnitedHealth Group is deploying artificial intelligence across its operations as part of a roughly $3 billion AI initiative including AI-powered voice bots to communicate with doctors.

Buy UNH riding rotation into healthcare as hardware saturates; Q2 earnings beat potential drives price to $425-450.

UnitedHealth Group is placing artificial intelligence at the center of its turnaround strategy to improve efficiency and speed up customer care approvals.

Luigi Mangione's lawyers withdrew a plan for a psychiatric defense at his upcoming state murder trial in the shooting death of a UnitedHealth Group executive.